Cleavage of human 7-domain VCAM-1 (CD106) by thrombin

Steven R. Barthel; Mats W. Johansson; Douglas S. Annis; Deane F. Mosher

doi:10.1160/TH05-12-0812

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(05): 873-880
DOI: 10.1160/TH05-12-0812

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Cleavage of human 7-domain VCAM-1 (CD106) by thrombin

Steven R. Barthel

¹Departments of Biomolecular Chemistry

²Medicine, University of Wisconsin, Madison, Wisconsin, USA

,

Mats W. Johansson

²Medicine, University of Wisconsin, Madison, Wisconsin, USA

,

Douglas S. Annis

²Medicine, University of Wisconsin, Madison, Wisconsin, USA

,

Deane F. Mosher

¹Departments of Biomolecular Chemistry

²Medicine, University of Wisconsin, Madison, Wisconsin, USA

› Author Affiliations

Abstract

Summary

Vascular cell adhesion molecule 1 (VCAM-1,CD106) is expressed as a type I transmembrane integrin counter-receptor on activated endothelium and mediates white blood cell attachment. The alternatively spliced 7-domain (7d) form of VCAM-1 contains a potential thrombin cleavage site. Thrombin proteolysis of 7d-VCAM-1 may help regulate adhesive activity of VCAM-1. We determined whether 7d-VCAM-1 is proteolyzed and rendered inactive by thrombin. Recombinant extracellular domain of 7d-VCAM-1 was cleaved by thrombin to generate 33- and 44-kDa products. Cleavage was in the sequence PGPR/IAAQIG near the N-terminal border of the alternatively spliced fourth immunoglobulin (Ig)-like module. There was no cleavage of 6d-VCAM-1 lacking the fourth module. Expression of full-length 7d-VCAM-1 presented on Chinese hamster ovary (CHO) monolayers, as detected by flow cytometry with an antibody directed to Ig-like modules 1–3, was reduced by thrombin treatment whereas there was no reduction in the expression of fulllength 6d-VCAM-1. Adhesion of blood eosinophils to full-length 7d-VCAM-1 was reduced after treatment of CHO cells with thrombin, whereas adhesion to full-length 6d-VCAM-1 was not affected. We conclude that cleavage of 7d-VCAM-1 by thrombin is a potential mechanism for differential regulation of VCAM-1 splice forms in white blood cell adhesion and trafficking.

Keywords

Adhesion molecules - adhesion receptors/integrins - leukocyte function/activation - leukocyte trafficking/recruitment - thrombin

Full Text

References

References
1 Miyake K, Medina K, Ishihara K. et al. A VCAMlike adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J Cell Biol 1991; 114: 557-65.
2 Simmons PJ, Masinovsky B, Longenecker BM. et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992; 80: 388-95.
3 Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989; 246: 1303-6.
4 Alon R, Kassner PD, Carr MW. et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 1995; 128: 1243-53.
5 Yamamoto H, Nagata M, Sakamoto Y. CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1. Ann Allergy Asthma Immunol 2005; 94: 292-300.
6 Levesque JP, Takamatsu Y, Nilsson SK. et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-97.
7 Schweitzer KM, Drager AM, van der Valk P. et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996; 148: 165-75.
8 Grayson MH, Van der Vieren M, Sterbinsky SA. et al. αdβ2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 1998; 188: 2187-91.
9 Matsumoto K, Sterbinsky SA, Bickel CA. et al. Regulation of α4 integrin-mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1. J Allergy Clin Immunol 1997; 99: 648-56.
10 Walsh GM, Symon FA, Lazarovils AL. et al. Integrin α4β7 mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. Immunology 1996; 89: 112-9.
11 Tachimoto H, Bochner BS. The surface phenotype of human eosinophils. Chem Immunol 2000; 76: 45-62.
12 Chiu HH, Crowe DT, Renz ME. et al. Similar but nonidentical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with α4β1 and α4β7 under different activity states. J Immunol 1995; 155: 5257-67.
13 Pigott R, Dillon LP, Hemingway IH. et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.
14 Wellicome SM, Kapahi P, Mason JC. et al. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993; 92: 412-8.
15 Rose DM, Cardarelli PM, Cobb RR. et al. Soluble VCAM-1 binding to α4 integrins is cell-type specific and activation dependent and is disrupted during apoptosis inT cells. Blood 2000; 95: 602-9.
16 Garton KJ, Gough PJ, Philalay J. et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alphaconverting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459-64.
17 Hession C, Tizard R, Vassallo C. et al. Cloning of an alternate form of vascular cell adhesion molecule-1 (VCAM1). J Biol Chem 1991; 266: 6682-5.
18 Osborn L, Vassallo C, Browning BG. et al. Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (α4β1). J Cell Biol 1994; 124: 601-8.
19 Pepinsky B, Hession C, Chen LL. et al. Structure/ function studies on vascular cell adhesion molecule-1. J Biol Chem 1992; 267: 17820-6.
20 Jenny RJ, Mann KG, Lundblad RL. A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa. Protein Expr Purif 2003; 31: 1-11.
21 Di Cera E, Cantwell AM. Determinants of thrombin specificity. Ann NY Acad Sci 2001; 936: 133-46.
22 Johansson MW, Lye MH, Barthel SR. et al. Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am J Respir Cell Mol Biol 2004; 31: 413-22.
23 Chuluyan HE, Osborn L, Lobb R. et al. Domains 1 and 4 of vascular cell adhesion molecule-1 (CD106) both support very late activation antigen-4 (CD49d/CD29)-dependent monocyte transendothelial migration. J Immunol 1995; 155: 3135-44.
24 Hansel TT, De Vries IJ, Iff T. et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991; 145: 105-10.
25 Meerschaert J, Vrtis RF, Shikama Y. et al. Engagement of α4β7 integrins by monoclonal antibodies or ligands enhances survival of human eosinophils in vitro . J Immunol 1999; 163: 6217-27.
26 Sedgwick JB, Calhoun WJ, Vrtis RF. et al. Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol 1992; 149: 3710-8.
27 Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. Faseb J 1995; 09: 946-55.
28 Sadler JE, Lentz SR, Sheehan JP. et al. Structurefunction relationships of the thrombin-thrombomodulin interaction. Haemostasis 1993; 23 (Suppl. 01) 183-93.
29 Vonderheide RH, Tedder TF, Springer TA. et al. Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J Cell Biol 1994; 125: 215-22.
30 Clements JM, Newham P, Shepherd M. et al. Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. J Cell Sci 1994; 107: 2127-35.
31 Yusuf-Makagiansar H, Anderson ME, Yakovleva TV. et al. Inhibition of LFA-1/ICAM-1 and VLA- 4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002; 22: 146-67.
32 Terada M, Kelly EA, Jarjour NN. Increased thrombin activity after allergen challenge: a potential link to airway remodeling?. Am J Respir Crit Care Med 2004; 169: 373-7.
33 Zangrilli JG, Shaver JR, Cirelli RA. et al. sVCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late phase response. Am J Respir Crit Care Med 1995; 151: 1346-53.
34 Kitani A, Nakashima N, Matsuda T. et al. T cells bound by vascular cell adhesion molecule-1/CD106 in synovial fluid in rheumatoid arthritis: inhibitory role of soluble vascular cell adhesion molecule-1 in T cell activation. J Immunol 1996; 156: 2300-8.
35 Kitani A, Nakashima N, Izumihara T. et al. Soluble VCAM-1 induces chemotaxis of Jurkat and synovial fluidT cells bearing high affinity very late antigen-4. J Immunol 1998; 161: 4931-8.
36 Tokuhira M, Hosaka S, Volin MV. et al. Soluble vascular cell adhesion molecule1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1122-33.
37 Busse WW, Nagata M, Sedgwick JB. Characteristics of airway eosinophils. Eur Respir J Suppl 1996; 22: 132s-135s.
38 Terry RW, Kwee L, Levine JF. et al. Cytokine induction of an alternatively spliced murine vascular cell adhesion molecule (VCAM) mRNA encoding a glycosylphosphatidylinositol-anchored VCAM protein. Proc Natl Acad Sci USA 1993; 90: 5919-23.
39 Kinashi T, St Pierre Y, Springer TA. Expression of glycophosphatidylinositol-anchored and -non-anchored isoforms of vascular cell adhesion molecule1 in murine stromal and endothelial cells. J Leukoc Biol 1995; 57: 168-73.
40 Kilger G, Needham LA, Nielsen PJ. et al. Differential regulation of α4 integrin-dependent binding to domains 1 and 4 of vascular cell adhesion molecule-1. J Biol Chem 1995; 270: 5979-84.
41 Needham LA, Van Dijk S, Pigott R. et al. Activation dependent and independent VLA-4 binding sites on vascular cell adhesion molecule-1. Cell Adhes Commun 1994; 02: 87-99.
42 Abe Y, Ballantyne CM, Smith CW. Functions of domain 1 and 4 of vascular cell adhesion molecule-1 in a4 integrin-dependent adhesion under static and flow conditions are differentially regulated. J Immunol 1996; 157: 5061-9.